Capstone Q2 Revenue Surges 67%, Operating Income Turns Positive, Going Concern Doubt Alleviated

summarizeSummary

Capstone's Q2 revenue surged 67% to $21.5M and it swung to an operating profit, leading management to conclude that going concern doubt is alleviated. However, the stock is at $0.33, a reverse split is authorized, and post-quarter the convertible note conversion price was cut to $0.2949, threatening massive dilution.

check_boxKey Events · Earnings and Guidance · CAPS

• Q2 Revenue +67%, Operating Profit Restored

  Net sales reached $21.5M vs $12.9M a year ago, driven by acquisitions. Gross profit nearly doubled to $6.0M, and the company posted operating income of $432K compared to a $260K loss in Q2 2025.

• Going Concern Doubt Alleviated

  Management concluded that cost cuts ($2M annualized), product expansion, expected tariff refunds ($438K), and availability under the $20M equity line of credit alleviate the substantial doubt about continuing as a going concern that was raised in the prior 10-Q.

• Convertible Note Conversion Price Slashed to $0.2949

  After the quarter, the conversion price on the remaining $1.9M of senior secured convertible notes was reduced to $0.2949. At that price, the notes convert into approximately 6.4M shares — roughly 31% of the 20.6M shares currently outstanding — at the holder's option.

• Massive Insider Stock Grants and Potential Dilution

  The company granted 4.8M restricted shares to executives and directors post-quarter and authorized exchanges of Series Z preferred stock for up to 15.75M common shares at a 3% premium to market, with an 18-month lock-up.

auto_awesomeAnalysis · CAPS · Trade & Services

A sharp operational turnaround marked Capstone's Q2 2026, with net sales jumping 67% to $21.5 million and the company swinging to a $432,000 operating profit from a $260,000 loss a year ago. Gross margin expanded to 27.9%, helped by a $438,000 tariff refund. More critically, management concluded that its cost-cutting, product expansion, tariff refunds, and available equity line of credit alleviate the substantial doubt about the company's ability to continue as a going concern that was raised in the prior quarter. The stock trades at $0.33, and the company remains non-compliant with Nasdaq's $1 minimum bid price rule, but shareholders have authorized a reverse split. After the quarter, the conversion price on the remaining $1.9 million of toxic convertible notes was slashed to $0.2949, setting up massive potential dilution — roughly 6.4 million shares, or about 31% of the current outstanding count, could be issued at the holder's option. The company also granted 4.8 million restricted shares to insiders and authorized exchanges that could add up to 15.75 million more shares. The operating improvement is real, but the capital structure remains under severe pressure.